A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 538 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 Your Microbiome and Cancer: What to Know December 23, 2020 Is AI Ready to Play a Leading Role in Colorectal Cancer... October 10, 2023 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Load more HOT NEWS NICE doesn’t recommend olaparib for patients with certain prostate cancers Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... New on NCI’s Websites, March 2020
